Does cancer risk affect health-related quality of life in patients with Barrett's esophagus?

Gastrointestinal Endoscopy

Volumn 65, Issue 1, 2007, Pages 16-25

  Gerson, Lauren B ^a   Ullah, Nighat ^a   Hastie, Trevor ^a   Goldstein, Mary K ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CLINICAL TRIAL; COMPUTER PROGRAM; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SHORT FORM 36;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RISK; SOFTWARE;

EID: 33845502572     PISSN: 00165107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gie.2006.05.018     Document Type: Article

References (52)

1. Paull A., Trier J.S., Dalton M.D., et al. The histologic spectrum of Barrett's esophagus. N Engl J Med 295 (1976) 476-480
2. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
3. Koop H. Reflux disease and Barrett's esophagus. Endoscopy 32 (2000) 101-107
4. Gerson L.B., Shetler K., and Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic adults. Gastroenterology 123 (2002) 461-467
5. O'Connor J.B., Falk G.W., and Richter J.E. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 94 (1999) 2037-2042
6. Drewitz D.J., Sampliner R.E., and Garewal H.S. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 92 (1997) 212-215
7. Revicki D.A., Wood M., Maton P.N., et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 104 (1998) 252-258
8. Johanson J.F., Siddique R., Damiano A.M., et al. Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. Dig Dis Sci 47 (2002) 2574-2578
9. Gold M.R., Patrick D.L., Torrance G.W., et al. Identifying and valuing outcomes. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-effectiveness in health and medicine (1996), Oxford University Press, New York 82-134
10. Gerson L.B., Ullah N., Hastie T., et al. Patient-derived health state utilities for gastroesophageal reflux disease. Am J Gastroenterol 100 (2005) 524-533
11. Nease Jr. R.F., Kneeland T., O'Connor G.T., et al. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA 273 (1995) 1185-1190
12. Lewis E.F., Johnson P.A., Johnson W., et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 20 (2001) 1016-1024
13. Blumenschein K., and Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol 80 (1998) 189-194
14. Sampliner R.E. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 97 (2002) 1888-1895
15. Corley D.A., Levin T.R., Habel L.A., et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 122 (2002) 633-640
16. Peters J.H., Clark G.W., Ireland A.P., et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 108 (1994) 813-821
17. Goldstein M.K., and Tsevat J. Applying utility assessment at the "bedside.". In: Chapman G., and Sonnenberg F. (Eds). Decision making in health care: theory, psychology, and applications (2000), Cambridge Press, Cambridge 313-333
18. Stalmeier P.F., Goldstein M.K., Holmes A.M., et al. What should be reported in a methods section on utility assessment?. Med Decis Making 21 (2001) 200-207
19. Goldstein MK, Tsevat J. Assessing desirability of outcomes states for medical decision making and cost-effectiveness analyses 2003:1-14. Available from: http://symptomresearch.nih.gov.
20. United States Life Tables 2002, NVSR Volume 53, Number 6. 39 pp. (PHS) 2005-1120. Available from: http://www.cdc.gov/nchs/products/pubs/pubd/lftbls/life/1966.htm.
21. Sumner W., Nease R., and Littenberg B. U-titer: a utility assessment tool. Proc Annu Symp Comput Appl Med Care (1991) 701-705
22. Harvard Risk Analysis Website. Available from: http://www.hcra.harvard.edu/.
23. Clarke G.A., Jacobson B.C., Hammett R.J., et al. The indications, utilization and safety of gastrointestinal endoscopy in an extremely elderly patient cohort. Endoscopy 33 (2001) 580-584
24. Sieg A., Hachmoeller-Eisenbach U., and Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. Gastrointest Endosc 53 (2001) 620-627
25. Lenert L.A., Cher D.J., Goldstein M.K., et al. The effect of search procedures on utility elicitations. Med Decis Making 18 (1998) 76-83
26. Fryback D.G., and Lawrence Jr. W.F. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. Med Decis Making 17 (1997) 276-284
27. Harris RA, Nease Jr, RF. The importance of patient preferences for comorbidities in cost-effectiveness analyses. J Health Econ 1997;16:113-9.
28. Weston A.P., Badr A.S., and Hassanein R.S. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 94 (1999) 3413-3419
29. Schnell T.G., Sontag S.J., Chejfec G., et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 120 (2001) 1607-1619
30. Weston A.P., Sharma P., Topalovski M., et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 95 (2000) 1888-1893
31. Sharma P., Morales T.G., Bhattacharyya A., et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol 92 (1997) 2012-2016
32. Streitz Jr. J.M., Andrews Jr. C.W., and Ellis Jr. F.H. Endoscopic surveillance of Barrett's esophagus. Does it help?. J Thorac Cardiovasc Surg 105 (1993) 383-387
33. Ellis Jr. F.H., Heatley G.J., Krasna M.J., et al. Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg 113 (1997) 836-846
34. Scott Bolton J., Wu T.T., and Yeo C.J. Esophagectomy for adenocarcinoma in patients 45 years of age and younger. J Gastrointest Surg 5 (2001) 620-625
35. Hulscher J.B., van Sandick J.W., de Boer A.G., et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347 (2002) 1662-1669
36. Ludwig D.J., Thirlby R.C., and Low D.E. A prospective evaluation of dietary status and symptoms after near-total esophagectomy without gastric emptying procedure. Am J Surg 181 (2001) 454-458
37. Parker E.F., Reed C.E., Marks R.D., et al. Chemotherapy, radiation therapy, and resection for carcinoma of the esophagus. Long-term results. J Thorac Cardiovasc Surg 98 (1989) 1037-1042
38. Wiklund I.K., Junghard O., Grace E., et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 583 (1998) 41-49
39. Locke G.R., Talley N.J., Weaver A.L., et al. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 69 (1994) 539-547
40. Stewart A.L., Greenfield S., Hays R.D., et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 262 (1989) 907-913
41. Mosteller F., and Tukey J. Data analysis and regression (1977), Addison-Wesley, Boston
42. Ware Jr. J.E., Snow K.K., Kosinski M., et al. SF-36 health survey manual and interpretation guide (1993), QualityMetric, Boston
43. Farup C., Kleinman L., Sloan S., et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 161 (2001) 45-52
44. Eloubeidi M.A., and Provenzale D. Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol 95 (2000) 1881-1887
45. Nichol M.B., Sengupta N., and Globe D.R. Evaluating quality-adjusted life years: estimation of the Health Utility Index (HUI2) from the SF-36. Med Decis Making 21 (2001) 105-112
46. Melsop K.A., Boothroyd D.B., and Hlatky M.A. Quality of life and time trade-off utility measures in patients with coronary artery disease. Am Heart J 145 (2003) 36-41
47. Stavem K. Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual Life Res 8 (1999) 45-54
48. Hornberger J.C., Redelmeier D.A., and Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 45 (1992) 505-512
49. Dolan P., Gudex C., Kind P., et al. Valuing health states: a comparison of methods. J Health Econ 15 (1996) 209-231
50. Heath C., and Tversky A. Preference and belief: ambiguity and competence in choice under uncertainty. J Risk Uncertain 4 (1991) 5-28
51. Tsevat J., Goldman L., Soukup J.R., et al. Stability of TTO utilities in survivors of myocardial infarction. Med Decis Making 13 (1993) 161-165
52. Reid B.J., Levine D.S., Longton G., et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95 (2000) 1669-1676